Innovent Begins Phase 3 Trials for IBI354 in Treating Platinum-Resistant Ovarian Cancer Innovent Biologics has successfully dosed its first participant in a Phase 3 clinical trial for IBI354, targeting platinum-resistant ovarian cancer. This study is a significant step in oncology treatment.

Innovent Begins Phase 3 Trials for IBI354 in Treating Platinum-Resistant Ovarian Cancer #China #Suzhou #Innovent #IBI354 #HER2_ADC